Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 19228721)


Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.

Zhao Z, Liao G, Li Y, Zhou S, Zou H, Fernando S.

PLoS One. 2014 Nov 26;9(11):e114096. doi: 10.1371/journal.pone.0114096. eCollection 2014.


SEOM clinical guidelines for the treatment of renal cell carcinoma.

Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I.

Clin Transl Oncol. 2014 Dec;16(12):1043-50. doi: 10.1007/s12094-014-1219-1. Epub 2014 Oct 2.


Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies.

El-Mokadem I, Fitzpatrick J, Rai B, Cunningham J, Pratt N, Fleming S, Nabi G.

Biomed Res Int. 2014;2014:521380. doi: 10.1155/2014/521380. Epub 2014 Apr 30. Review.


Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer.

Stewart DJ, Nunez MI, Behrens C, Liu D, Lin YH, Lee JJ, Roth J, Heymach J, Swisher SG, Hong WK, Wistuba II.

J Thorac Oncol. 2014 May;9(5):675-84. doi: 10.1097/JTO.0000000000000148.


Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Wang L, Williamson SR, Wang M, Davidson DD, Zhang S, Baldridge LA, Du X, Cheng L.

Mol Cancer. 2014 Feb 26;13:39. doi: 10.1186/1476-4598-13-39.


Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.

Gowrishankar B, Cahill L, Arndt AE, Al-Ahmadie H, Lin O, Chadalavada K, Chaganti S, Nanjangud GJ, Murty VV, Chaganti RS, Reuter VE, Houldsworth J.

BJU Int. 2014 Dec;114(6):881-90. doi: 10.1111/bju.12643. Epub 2014 Jul 15.


Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.

van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, Blancafort P, Rots MG.

Br J Cancer. 2013 Mar 5;108(4):881-6. doi: 10.1038/bjc.2013.45. Epub 2013 Feb 12.


N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma.

Behnes CL, Hemmerlein B, Strauss A, Radzun HJ, Bremmer F.

Diagn Pathol. 2012 Aug 13;7:95. doi: 10.1186/1746-1596-7-95.


Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis.

Yokomizo A, Yamamoto K, Furuno K, Shiota M, Tatsugami K, Kuroiwa K, Naito S.

Oncol Lett. 2010 Nov;1(6):1073-1078. Epub 2010 Sep 23.


State of the science: an update on renal cell carcinoma.

Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK.

Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25. Review.


Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Hernandez-Yanez M, Heymach JV, Zurita AJ.

Curr Oncol Rep. 2012 Jun;14(3):221-9. doi: 10.1007/s11912-012-0231-2. Review.


Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.

Mester JL, Zhou M, Prescott N, Eng C.

Urology. 2012 May;79(5):1187.e1-7. doi: 10.1016/j.urology.2011.12.025. Epub 2012 Mar 3.


Repeat partial nephrectomy: surgical, functional and oncological outcomes.

Shuch B, Linehan WM, Bratslavsky G.

Curr Opin Urol. 2011 Sep;21(5):368-75. doi: 10.1097/MOU.0b013e32834964ea. Review.


Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer.

van der Gun BT, de Groote ML, Kazemier HG, Arendzen AJ, Terpstra P, Ruiters MH, McLaughlin PM, Rots MG.

Br J Cancer. 2011 Jul 12;105(2):312-9. doi: 10.1038/bjc.2011.231. Epub 2011 Jun 21.


Kidney cancer pathology in the new context of targeted therapy.

Allory Y, Culine S, de la Taille A.

Pathobiology. 2011;78(2):90-8. doi: 10.1159/000315543. Epub 2011 Jun 14. Review.


Tumor biology and prognostic factors in renal cell carcinoma.

Finley DS, Pantuck AJ, Belldegrun AS.

Oncologist. 2011;16 Suppl 2:4-13. doi: 10.1634/theoncologist.2011-S2-04. Review.


Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Roos FC, Evans AJ, Brenner W, Wondergem B, Klomp J, Heir P, Roche O, Thomas C, Schimmel H, Furge KA, Teh BT, Thüroff JW, Hampel C, Ohh M.

Am J Pathol. 2011 Feb;178(2):853-60. doi: 10.1016/j.ajpath.2010.10.033.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk